{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:13:40Z","timestamp":1791335620817,"version":"4.3.1"},"reference-count":20,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"28","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2019,10,1]]},"abstract":"<jats:sec><jats:title>PURPOSE<\/jats:title><jats:p> Antiangiogenic agents combined with chemotherapy have efficacy in the treatment of unresectable malignant pleural mesothelioma (MPM). Cediranib (AstraZeneca, Cheshire, United Kingdom), a vascular endothelial growth factor receptor and platelet-derived growth factor receptor inhibitor, demonstrated therapeutic potential in a prior phase I trial. We evaluated a phase II trial for efficacy. <\/jats:p><\/jats:sec><jats:sec><jats:title>PATIENTS AND METHODS<\/jats:title><jats:p> SWOG S0905 (ClinicalTrials.gov identifier: NCT01064648 ) randomly assigned cediranib or placebo with platinum-pemetrexed for six cycles followed by maintenance cediranib or placebo in unresectable chemotherapy-na\u00efve patients with MPM of any histologic subtype. Primary end point was Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 progression-free survival (PFS). Secondary end points included overall survival, PFS by modified RECIST v1.1, response (modified RECIST and RECIST v1.1), disease control, and safety\/toxicity. The trial was designed to detect a difference in RECIST v1.1 PFS at the one-sided 0.1 level using a stratified log-rank test. <\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p> Ninety-two eligible patients were enrolled (75% epithelioid and 25% biphasic or sarcomatoid). The cediranib arm had more grade 3 and 4 diarrhea, dehydration, hypertension, and weight loss. Cediranib improved PFS by RECIST v1.1 (hazard ratio, 0.71; 80% CI, 0.54 to 0.95; P = .062; 7.2 months v 5.6 months) and increased modified RECIST v1.1 response (50% v 20%; P = .006). By modified RECIST v1.1, cediranib numerically increased PFS (hazard ratio, 0.77; 80% CI, 0.59 to 1.02; P = .12; median, 6.9 months v 5.6 months). No significant difference in overall survival was observed. <\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p> The addition of cediranib to platinum-pemetrexed improved PFS by RECIST v1.1 and response rate by modified RECIST in patients with unresectable MPM. Whereas adding antiangiogenics to chemotherapy has been a successful strategy for some patients, the cediranib toxicity profile and small incremental survival benefit precludes additional development in MPM. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.19.00269","type":"journal-article","created":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T19:55:16Z","timestamp":1565121316000},"page":"2537-2547","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":49,"title":["Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Na\u00efve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905)"],"prefix":"10.1200","volume":"37","author":[{"given":"Anne S.","family":"Tsao","sequence":"first","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieling","family":"Miao","sequence":"additional","affiliation":[{"name":"SWOG Statistical Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio I.","family":"Wistuba","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Vogelzang","sequence":"additional","affiliation":[{"name":"US Oncology Comprehensive Cancer Centers of Nevada, Las Vegas, NV"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John V.","family":"Heymach","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank V.","family":"Fossella","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Lu","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario R.","family":"Velasco","sequence":"additional","affiliation":[{"name":"Cancer Care Specialists of Illinois, Decatur, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandy","family":"Box-Noriega","sequence":"additional","affiliation":[{"name":"Kaiser Permanente, Fresno, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G.","family":"Hueftle","sequence":"additional","affiliation":[{"name":"Montana Cancer Consortium, Billings, MT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirish","family":"Gadgeel","sequence":"additional","affiliation":[{"name":"University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary W.","family":"Redman","sequence":"additional","affiliation":[{"name":"SWOG Statistical Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Gandara","sequence":"additional","affiliation":[{"name":"University of California Davis Cancer Center, Sacramento, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Kelly","sequence":"additional","affiliation":[{"name":"University of California Davis Cancer Center, Sacramento, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.136"},{"key":"B2","first-page":"3364","volume":"5","author":"Zebrowski BK","year":"1999","journal-title":"Clin Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/path.824"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6690650"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/95.6.458"},{"key":"B6","first-page":"2929","volume":"61","author":"Pietras K","year":"2001","journal-title":"Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01238-6"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.9012"},{"key":"B9","volume-title":"Nintedanib + Pemetrexed\/Cisplatin in Patients With Unresectable MPM: Phase III Results From the LUME-Meso Trial","author":"Scagliotti G","year":"2018"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318229586e"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1096\/fj.03-0271fje"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.05.021"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh059"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318208c83d"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2307\/2529712"},{"key":"B16","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/JTO.0b013e3181fa8efd","volume":"6","author":"Brahmer JR","year":"2011","journal-title":"J Thorac Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1303116"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.11.1097"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1510\/icvts.2009.223255"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716948"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.19.00269","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T10:39:46Z","timestamp":1653820786000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.19.00269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,1]]},"references-count":20,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2019,10,1]]}},"alternative-id":["10.1200\/JCO.19.00269"],"URL":"https:\/\/doi.org\/10.1200\/jco.19.00269","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,1]]},"assertion":[{"value":"2019-07-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}